Logo image of BHST

BIOHARVEST SCIENCES INC (BHST) Stock Fundamental Analysis

NASDAQ:BHST - Nasdaq - CA09076J2074 - Common Stock - Currency: USD

6.46  -0.29 (-4.3%)

Fundamental Rating

2

BHST gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 35 industry peers in the Personal Care Products industry. BHST has a bad profitability rating. Also its financial health evaluation is rather negative. BHST is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BHST has reported negative net income.
BHST had a negative operating cash flow in the past year.
In the past 5 years BHST always reported negative net income.
BHST had a negative operating cash flow in each of the past 5 years.
BHST Yearly Net Income VS EBIT VS OCF VS FCFBHST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -66.58%, BHST is doing worse than 85.71% of the companies in the same industry.
BHST's Return On Equity of -415.37% is on the low side compared to the rest of the industry. BHST is outperformed by 82.86% of its industry peers.
Industry RankSector Rank
ROA -66.58%
ROE -415.37%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BHST Yearly ROA, ROE, ROICBHST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

BHST has a worse Gross Margin (54.00%) than 60.00% of its industry peers.
In the last couple of years the Gross Margin of BHST has grown nicely.
BHST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.45%
GM growth 5YN/A
BHST Yearly Profit, Operating, Gross MarginsBHST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

BHST does not have a ROIC to compare to the WACC, probably because it is not profitable.
BHST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BHST Yearly Shares OutstandingBHST Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 100M 200M 300M 400M
BHST Yearly Total Debt VS Total AssetsBHST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2M 4M 6M 8M 10M

2.2 Solvency

BHST has an Altman-Z score of -2.06. This is a bad value and indicates that BHST is not financially healthy and even has some risk of bankruptcy.
BHST has a Altman-Z score of -2.06. This is amonst the worse of the industry: BHST underperforms 91.43% of its industry peers.
BHST has a Debt/Equity ratio of 2.58. This is a high value indicating a heavy dependency on external financing.
BHST has a worse Debt to Equity ratio (2.58) than 82.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC7.75%
BHST Yearly LT Debt VS Equity VS FCFBHST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 -5M -10M

2.3 Liquidity

A Current Ratio of 0.80 indicates that BHST may have some problems paying its short term obligations.
BHST has a worse Current ratio (0.80) than 82.86% of its industry peers.
BHST has a Quick Ratio of 0.80. This is a bad value and indicates that BHST is not financially healthy enough and could expect problems in meeting its short term obligations.
BHST has a Quick ratio of 0.48. This is amonst the worse of the industry: BHST underperforms 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.48
BHST Yearly Current Assets VS Current LiabilitesBHST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 1M 2M 3M 4M 5M

More info and screens

7

3. Growth

3.1 Past

BHST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -734.76%.
The Revenue has grown by 111.68% in the past year. This is a very strong growth!
The Revenue has been growing by 217.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-734.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.51%
Revenue 1Y (TTM)111.68%
Revenue growth 3Y217.48%
Revenue growth 5YN/A
Sales Q2Q%101.88%

3.2 Future

BHST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.77% yearly.
Based on estimates for the next years, BHST will show a very strong growth in Revenue. The Revenue will grow by 88.58% on average per year.
EPS Next Y-4%
EPS Next 2Y31.18%
EPS Next 3Y31.77%
EPS Next 5YN/A
Revenue Next Year161.11%
Revenue Next 2Y107.4%
Revenue Next 3Y88.58%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BHST Yearly Revenue VS EstimatesBHST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
BHST Yearly EPS VS EstimatesBHST Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 0.2 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BHST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BHST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHST Price Earnings VS Forward Price EarningsBHST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHST Per share dataBHST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

BHST's earnings are expected to grow with 31.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.18%
EPS Next 3Y31.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BHST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHARVEST SCIENCES INC

NASDAQ:BHST (6/3/2025, 10:08:13 AM)

6.46

-0.29 (-4.3%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-27 2025-08-27
Inst Owners0.51%
Inst Owner ChangeN/A
Ins Owners17.79%
Ins Owner ChangeN/A
Market Cap111.95M
Analysts82.5
Price Target9.3 (43.96%)
Short Float %0.19%
Short Ratio0.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.3%
Min EPS beat(2)-43.84%
Max EPS beat(2)60.44%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.18%
Min Revenue beat(2)-29.7%
Max Revenue beat(2)-0.66%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.99
P/FCF N/A
P/OCF N/A
P/B 27.05
P/tB 27.05
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS1.29
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.58%
ROE -415.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.45%
GM growth 5YN/A
F-Score4
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 242.72%
Cap/Sales 12.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.8
Quick Ratio 0.48
Altman-Z -2.06
F-Score4
WACC7.75%
ROIC/WACCN/A
Cap/Depr(3y)257.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)37.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-734.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.51%
EPS Next Y-4%
EPS Next 2Y31.18%
EPS Next 3Y31.77%
EPS Next 5YN/A
Revenue 1Y (TTM)111.68%
Revenue growth 3Y217.48%
Revenue growth 5YN/A
Sales Q2Q%101.88%
Revenue Next Year161.11%
Revenue Next 2Y107.4%
Revenue Next 3Y88.58%
Revenue Next 5YN/A
EBIT growth 1Y21.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.8%
EBIT Next 3Y58.05%
EBIT Next 5YN/A
FCF growth 1Y3.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.22%
OCF growth 3YN/A
OCF growth 5YN/A